Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Division of Translational Medical Oncology

Prof. Dr. Stefan Fröhling


Translational oncology aims to enable the clinical application of cancer research results. This means new discoveries on the formation and development of cancer diseases should quickly benefit patients in the form of improved diagnostic and treatment options. Bridging this gap between science and medicine requires close cooperation between basic researchers and physicians who are involved both in treatment and research. This allows for new scientific concepts to be implemented (“bench to bedside”), and questions that are asked in the clinic can be directly transferred to researchers in the form of a reverse translation (“bedside to bench”). Patients benefit from improved diagnostics, innovative therapies, and access to clinical studies.

The activities of our department include all aspects of the translational oncology continuum. In the area of preclinical translation, we are working on numerous application-oriented lab projects dealing with the pathogenesis of different cancers, in order to identify points of attack for targeted treatments and new diagnostic options.

In the area of clinical translation, we deal mainly with the development and systematic use of tools for comprehensive molecular, cellular, and functional characterization of individual tumors, and we are involved in the design and implementation of innovative, investigator-initiated trials.

The focus of our preclinical and clinical work lies within the field of medical oncology. In addition, and particularly in connection with the increasing use of very broad molecular, cellular, and functional diagnostics, we also pursue close interaction with other disciplines such as radiation oncology and the different surgical specialties to assist in implementing these treatments as accurately as possible and in line with the patients’ individual needs.

Within the scope of our preclinical research and in close cooperation with the Division of Applied Functional Genomics, we pursue the goal of developing new diagnostic procedures and more targeted treatment approaches by investigating the molecular and functional properties of different cancers.

Current areas of activity include

  1. The continuous development and refinement of strategies for the multidimensional characterization of individual tumors within the framework of the NCT/DKTK MASTER Program, which includes creating strategies for the systematic functional annotation of newly discovered genetic changes;
  2. The detection of essential signaling pathways in bone and soft-tissue sarcomas through integrative genome and transcriptome analyses as well as functional genomic screens;
  3. The search for new therapeutic targets in acute myeloid leukemia with special consideration of subtypes with therapeutically intractable genetic changes such as MLL rearrangements, inactivating mutations of GATA2, or aberrant CDX2 expression;
  4. The detailed analysis of signaling pathways that are activated by oncogenic KRAS mutations.


Prof. Dr. Stefan Fröhling
Translational Medical Oncology (B340)
Deutsches Krebsforschungszentrum
und Nationales Centrum für Tumorerkrankungen (NCT)
Im Neuenheimer Feld 460
69120 Heidelberg

Selected Publications

  • Gröschel S. et al. (2019). Defective homologous recombination DNA repair as therapeutic target in advanced chordoma. Nat Commun, 10:1635.
  • Trautmann M. et al. (2019). Requirement for YAP1 signaling in myxoid liposarcoma. EMBO Mol Med, 11:e9889.
  • Heining C. et al. (2018). NRG1 fusions in KRAS wild-type pancreatic cancer. Cancer Discov, 8:1087-1095.
  • Chudasama P. et al. (2018) Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nat Commun, 9:144.
to top
powered by webEdition CMS